Cowan Elvia — SEC insider filings
SEC reporting owner CIK 1960048. 21 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2023-03-03 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 15 legs across 10 filings — 67,693 shares, $5,047,834 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 46.
- Largest priced transaction: sale of 19,000 shares @ $86.74 ($1,648,060) in Vaxcyte, Inc., filed 2026-10-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | SVP, Finance & CAO | 21 | — | 15 legs · 67,693 sh · $5,047,834 | 46 |
Insider filings — Cowan Elvia
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 3,000 @ $25.92 · Sale (S): 2,414 @ $60.77 · Sale (S): 586 @ $61.55 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-10-07 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 19,000 @ $25.92 · Sale (S): 19,000 @ $86.74 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 1,327 @ $60.36 | EDGAR |
| 2026-09-02 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 243 @ $60.74 · Tax withholding (F): 326 @ $61.58 | EDGAR |
| 2026-04-08 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 3,000 @ $25.92 · Sale (S): 3,000 @ $60 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 1,487 @ $55.39 · Sale (S): 405 @ $56.26 | EDGAR |
| 2026-03-11 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 495 @ $59.32 · Option exercise (M): 2,500 @ $25.92 · Sale (S): 2,500 @ $58.59 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 10,681 @ $0 · Option exercise (M): 7,716 @ $25.92 · Tax withholding (F): 243 @ $61.98 · Tax withholding (F): 326 @ $61.98 · Grant/award (A): 17,855 (derivative) @ $0 · Option exercise (M): 7,716 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 4,907 @ $47.90 · Sale (S): 6,716 @ $47.94 · Gift (G): 1,000 @ $0 | EDGAR |
| 2025-09-10 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 482 @ $32.41 | EDGAR |
| 2025-09-04 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 242 @ $31.56 · Tax withholding (F): 325 @ $31.56 | EDGAR |
| 2025-08-29 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 2,810 @ $0 · Grant/award (A): 9,743 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 5,379 @ $0 · Tax withholding (F): 242 @ $73.02 · Tax withholding (F): 325 @ $72.10 · Grant/award (A): 17,961 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 7,716 @ $25.92 · Option exercise (M): 7,716 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 11,900 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 5,000 @ $25.92 · Sale (S): 5,000 @ $107.67 · Tax withholding (F): 1,145 @ $110.15 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 5,000 @ $25.92 · Sale (S): 5,000 @ $85 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-07-09 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 5,000 @ $25.92 · Sale (S): 5,000 @ $80 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 5,400 @ $0 · Option exercise (M): 11,000 @ $25.92 · Sale (S): 2,322 @ $73.08 · Sale (S): 4,455 @ $73.69 · Sale (S): 4,901 @ $74.90 · Tax withholding (F): 324 @ $71.55 · +2 more | EDGAR |
| 2023-09-06 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 627 @ $51 | EDGAR |
| 2023-03-03 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 7,250 @ $0 · Grant/award (A): 43,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-04-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1960048 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs